Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

General Biologicals Corp. (4117) Financial Statements

General Biologicals Corp. Financial Overview

General Biologicals Corp.'s market cap is currently NT$552.43M. The company's EPS TTM is NT$8.87; its P/E ratio is 0.85; General Biologicals Corp. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total RevenueNT$ 215.74MNT$ 251.93MNT$ 264.82MNT$ 370.46MNT$ 551.66M
Gross ProfitNT$ 59.62MNT$ 7.54MNT$ 62.71MNT$ 171.85MNT$ 281.94M
Operating IncomeNT$ -218.37MNT$ -213.14MNT$ -169.94MNT$ -40.87MNT$ 43.79M
EBITDANT$ 604.30MNT$ -170.71MNT$ -139.06MNT$ 7.99MNT$ 85.34M
Net IncomeNT$ 465.84MNT$ -220.82MNT$ -198.83MNT$ -53.19MNT$ 44.14M
Balance Sheet
Cash & Short-Term InvestmentsNT$ 634.75MNT$ 251.65MNT$ 217.12MNT$ 351.08MNT$ 369.82M
Total AssetsNT$ 4.87BNT$ 3.41BNT$ 2.54BNT$ 1.55BNT$ 1.26B
Total DebtNT$ 2.50BNT$ 2.31BNT$ 549.51MNT$ 470.13MNT$ 454.17M
Net DebtNT$ 2.25BNT$ 2.06BNT$ 332.39MNT$ 207.95MNT$ 145.40M
Total LiabilitiesNT$ 4.00BNT$ 3.12BNT$ 2.04BNT$ 857.51MNT$ 529.79M
Stockholders' EquityNT$ 870.69MNT$ 284.59MNT$ 495.13MNT$ 690.52MNT$ 731.51M
Cash Flow
Free Cash FlowNT$ -302.81MNT$ -1.64BNT$ -199.33MNT$ -23.60MNT$ -85.85M
Operating Cash FlowNT$ -127.26MNT$ -116.11MNT$ 225.68MNT$ 225.01MNT$ 38.97M
Investing Cash FlowNT$ -183.92MNT$ -1.56BNT$ -342.31MNT$ -277.91MNT$ -75.76M
Financing Cash FlowNT$ 307.44MNT$ 1.71BNT$ 72.37MNT$ -9.74MNT$ -4.26M

Currency in TWD

General Biologicals Corp. Earnings and Revenue History

-300M0300M600M-120 %0 %120 %240 %EarningsProfit Margin2019202020212022202320242025RevenueEarningsProfit Margin
Income Statement >

General Biologicals Corp. Liabilities to Assets

02B4B6B0 %40 %80 %120 %LiabilitiesLiabilities to Assets2019202020212022202320242025AssetsLiabilitiesLiabilities to Assets
Balance Sheet >

General Biologicals Corp. Cash Flow

-2B-1B01B2B2019202020212022202320242025OperatingInvestingFinancing
Cash Flow >

General Biologicals Corp. Forecast EPS vs Actual EPS

Earnings >